BIONOMICS LIMITED (ASX: BNO)
About Bionomics and glimpse of financial position
Bionomics Limited (ASX: BNO) primarily has operations into two segments named: drug discovery & development as well as contract services. The company is having drug discovery platforms named ionX as well as MultiCore. These platforms help the company in achieving a competitive edge with respect to underserved therapeutic areas. The company has been working very closely with Merck & Co. Inc. or MSD. The products portfolio of Bionomics and MSD have been made in a form which could help for cognitive dysfunction. Bionomics garnered revenues amounting to $3.9 million in FY2018 of which drug discovery and development segment contributed $1.2 million while revenues from the contract services amounted to $7.1 million.
However, intercompany revenues which were considered while calculating the contract services revenue amounted to $4.5 million. The total revenues mentioned-above have been garnered after excluding the intercompany revenues. The company’s corporate segment generated $0.2 million in FY2018.
The FY2018 revenues represent the fall of 79% on the YoY (year-over-year) basis. The company’s loss after tax stood at $25.1 million while in the previous year it was $6.7 million.
What to expect moving forward?
According to the top management of Bionomics, the company’s key areas of focus would be BNC210 as well as preclinical programs. The management expects that the company currently enjoys a healthy position to finance the trial runs of BNC210 as well as to base the crucial relationship with MSD. The company would be monetizing oncology programs which would help in boosting shareholders’ value.
NANOSONICS LIMITED (ASX: NAN)
About Nanosonics Limited
Nanosonics Limited (ASX: NAN) is in the business of developing solutions which help to control infection. At the end of June 30, 2018, the company had 225 employees spanning across regions like France, Germany, Canada, US, UK as well as Australia. According to the management, the new studies coupled with the guidelines helped the company as traction for Trophon got strengthened in FY2018. During the same period, the company witnessed a YoY increase of 25% in its installations to 17,740 units. The robust growth with respect to installations was witnessed in the Europe/Middle East/Africa or EMEA region i.e. 49% YoY. However, other regions like North America and the Asia Pacific saw the growth of 26% and 9.4%, respectively.
How Nanosonics plans to achieve growth?
Nanosonics is expected to witness positive momentum moving forward. The company is expected to witness further increase in the installations in FY 2019 with respect to the North America region. Moreover, the growth could also come from the European region. This growth would likely be supported by fresh and new instructions to come to France and with the help of trophon2 launch. New instructions which would be coming in Germany and UK’s MES program would also help the company to attract growth from Europe.
TELIX PHARMACEUTICALS LIMITED (ASX: TLX)
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (ASX: TLX) is a company which is in the business of development of MTR (molecularly targeted radiation) products. These products help in the meeting the needs related to cancer which is yet to be dealt with. The company presently serves markets like US, Australia, Belgium, United Kingdom, Japan, Germany as well as Singapore. In 1H 2018, the operations of the company were primarily focused towards three primary assets. These assets have been TLX-250, TLX-591 as well as TLX-101.
In 1H 2018, the company garnered total income amounting to $5.28 million. In the June quarter, the company’s cash used towards its operations were A$4.5 million. The company incurred A$3.2 million towards the payment related to the research and development or R&D. The company is in the process of making oncology products which would cure the prostate, renal as well as brain cancer.
What to expect moving forward?
The group’s Glioblastoma Study, acquisition of Atlab Pharma and overseas funding are expected to provide support going forward.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.